World's Best Scientists 2026 revealed!
Gert Van Assche

Gert Van Assche

D-Index & Metrics

Medicine

D-Index
113
Citations
63749
World Ranking
4851
National Ranking
50

Gert Van Assche publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gert Van Assche sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 765 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gert Van Assche D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gert Van Assche sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 113 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gert Van Assche is affiliated with KU Leuven in Belgium and has a research profile strongly focused on inflammatory and autoimmune disorders, particularly inflammatory bowel disease (IBD). Their work spans several interconnected fields including medicine, biochemistry, genetics, and molecular biology.

The scientist's research output features a considerable emphasis on subfields such as genetics, epidemiology, surgery, immunology, and molecular biology. This multidisciplinary approach underpins investigations into complex disease mechanisms and treatment strategies.

Several main topics characterize their research:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Autoimmune and Inflammatory Disorders
  • IL-33, ST2, and ILC Pathways
  • Eosinophilic Esophagitis
  • Pharmacological Effects of Natural Compounds
  • Gastrointestinal Bleeding Diagnosis and Treatment

Gert Van Assche has contributed to numerous scientific publications, including recent papers such as:

  • "Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease" (2020), published in Gastroenterology
  • "Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update" (2020), published in Digestion
  • "Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies" (2020), published in Clinical Gastroenterology and Hepatology
  • "A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis" (2020), published in Inflammatory Intestinal Diseases
  • "Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium" (2020), published in Frontiers in Immunology

The publication venues where the scientist frequently publishes include:

  • Journal of Crohn's and Colitis
  • Gastroenterology
  • Clinical Gastroenterology and Hepatology
  • Inflammatory Intestinal Diseases
  • Scandinavian Journal of Gastroenterology

Collaborative work plays a significant role in Gert Van Assche's research, with frequent co-authors being:

  • Séverine Vermeire
  • Marc Ferrante
  • Gert De Hertogh
  • Brecht Creyns
  • Jan Ceuppens

Best Publications

  • Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

    Filip Baert;Maja Noman;Severine Vermeire;Gert Van Assche

  • Vedolizumab as induction and maintenance therapy for ulcerative colitis.

    Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer

  • 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

    Fernando Gomollón;Axel Dignass;Vito Annese;Herbert Tilg

  • Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

    L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch

  • Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

    Marco Daperno;Geert D'Haens;Gert Van Assche;Filip Baert

  • Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

    Geert D'Haens;Filip Baert;Gert van Assche;Philip Caenepeel

  • Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

    Axel Dignass;James O. Lindsay;Andreas Sturm;Alastair Windsor

  • Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

    William J. Sandborn;Gert van Assche;Walter Reinisch;Jean–Frederic Colombel

  • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

    Gert Van Assche;Axel Dignass;Julian Panes;Laurent Beaugerie

  • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

    Gert Van Assche;Axel Dignass;Walter Reinisch;C. Janneke van der Woude

  • Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease

    Gert Van Assche;Marc Van Ranst;Raphael Sciot;Bénédicte Dubois

  • Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 1: Definitions and Diagnosis

    Axel Dignass;Rami Eliakim;Fernando Magro;Christian Maaser

  • Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

    Julián Panés;Damián García-Olmo;Gert Van Assche;Jean Frederic Colombel

  • Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

    Geert D'Haens;Marc Ferrante;Severine Vermeire;Filip Baert

  • Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.

    Filip Baert;Liesbeth Moortgat;Gert Van Assche;Philip Caenepeel

  • Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

    Niels Vande Casteele;Marc Ferrante;Gert Van Assche;Vera Ballet

  • Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

    Severine Vermeire;Maja Noman;Gert van Assche;Filip Baert

  • Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

    Fabian Schnitzler;Herma Fidder;Marc Ferrante;Maja Noman

  • Development of the Crohn's disease digestive damage score, the Lémann score†‡§

    Benjamin Pariente;Jacques Cosnes;Silvio Danese;William J. Sandborn

  • Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

    David Laharie;Arnaud Bourreille;Julien Branche;Matthieu Allez

Frequent Co-Authors

Jan Ceuppens
Jan Ceuppens KU Leuven
Geert R. D'Haens
Geert R. D'Haens University of Amsterdam
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai
William J. Sandborn
William J. Sandborn University of California, San Diego
Karel Geboes
Karel Geboes Ghent University Hospital
Frans Schuit
Frans Schuit KU Leuven
Walter Reinisch
Walter Reinisch Medical University of Vienna
Julián Panés
Julián Panés University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary pathways in healthcare is a smart move for those interested in studying Medicine in the USA. Online degrees now make it easier to advance your career while managing costs and maintaining flexibility.

A popular choice is a mha degree cost-effective program, which prepares graduates for management and leadership roles in healthcare organizations. Another option is to explore the cheapest dnp programs, offering advanced practice and specialized clinical opportunities for nurses looking to achieve the highest level of nursing practice.

For those interested in pharmaceutical sciences, pursuing an online pharmacist degree can open doors to clinical, research, and retail settings. Additionally, the growing field of health informatics presents robust career opportunities—earning a him degree online is ideal for those interested in managing patient data and healthcare information systems.

These online programs offer flexible schedules, accessibility, and often lower tuition costs, making them attractive options for diverse career goals in the healthcare sector.

Best Scientists Citing Gert Van Assche

Trending Scientists

Recently Published Articles